Using Leflunomide to treat children with Idiopathic Pulmonary Hemosiderosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of Leflunomide in treating children diagnosed with Idiopathic Pulmonary Hemosiderosis (IPH). Participants aged 6 months to 18 years will receive Leflunomide in combination with steroid therapy, while a control group will receive only steroids. The study will assess various indicators, including the frequency of pulmonary hemorrhage and lung function, over a one-year follow-up period. The goal is to determine if Leflunomide can improve clinical symptoms and inhibit lung function deterioration in these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age range from 6 months to 18 years old;
2. Diagnose as IPH;
3. Parents or guardians agree to treatment and sign a written informed consent form.

Exclusion Criteria:

1. Individuals who are allergic to any ingredients used in leflunomide tablets;
2. Complicated with serious basic diseases (such as systemic malignant diseases, heart failure, liver and kidney failure, immune deficiency, serious infectious diseases, Lung transplantation or other patients with immediate surgical indications);
3. Patients with other lung diseases;
4. Have a history of abnormal coagulation or abnormal coagulation function in the past;
5. Clinical trial participants who have previously participated in the treatment of flumiphene;
6. Other situations where the researcher deems it inappropriate to participate in the study.

Where it's running

• Sun Yat-sen Memorial Hospital of Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Study coordinator: Haiyan Wang, MD
• Email: wanghy78@mail.sysu.edu.cn
• Phone: 8613560489257

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing targeted therapy with triple therapy for rheumatoid arthritis patients not responding to standard treatments

  This study is testing whether adding a targeted therapy to existing medications works better than using a combination of traditional drugs for people with rheumatoid arthritis who haven't felt better with standard treatments.

  Recruiting Phase 4 University Hospital, Strasbourg, France · Strasbourg · NCT02714634

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.